Evidence map›Paper›PMID 33008091›Full record

ReviewInternational journal of molecular sciences2020

Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments.

Yen-Wen Shen, Yin-Hwa Shih, Lih-Jyh Fuh, Tzong-Ming Shieh

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06332612 (Repurposing Metformin for the Treatment of Oral Submucous Fibrosis), which is not on this map. Cited by 78 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06332612 phase1 / phase2completednot on this mapstarted 2024, after this paper: background citation

Repurposing Metformin for the Treatment of Oral Submucous Fibrosis: Unraveling Novel Signaling Pathways In Vitro and Advancing to Clinical Trial"

TypeinterventionalSponsorZiauddin UniversityRan2024 to 2025Enrolled30ConditionsOral Submucous FibrosisArmsMetformin Hydrochloride, betamethasone dipropionate, Pentoxifylline
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yen-Wen ShenSchool of Dentistry, China Medical University, Taichung 40402, Taiwan.
Yin-Hwa ShihDepartment of Healthcare Administration, Asia University, Taichung 41354, Taiwan.
Lih-Jyh FuhSchool of Dentistry, China Medical University, Taichung 40402, Taiwan.ORCID 0000-0003-3008-8165
Tzong-Ming ShiehSchool of Dentistry, China Medical University, Taichung 40402, Taiwan.
China Medical University · TWAsia University · TW

Funding

China Medical University CMU109-ASIA-12Ministry of Science and Technology, Taiwan MOST 108-2314-B-039-009-MY3Ministry of Science and Technology, Taiwan MOST 109-2314-B-468 -006 -MY3
6 · The paper itself

Abstract

Oral submucous fibrosis (OSF) is a collagen deposition disorder that affects a patient's oral function and quality of life. It may also potentially transform into malignancy. This review summarizes the risk factors, pathogenic mechanisms, and treatments of OSF based on clinical and bio-molecular evidence. Betel nut chewing is a major risk factor that causes OSF in Asia. However, no direct evidence of arecoline-induced carcinogenesis has been found in animal models. Despite identification of numerous biomarkers of OSF lesions and conducting trials with different drug combinations, clinicians still adopt conservative treatments that primarily focus on relieving the symptoms of OSF. Treatments focus on reducing inflammation and improving mouth opening to improve a patient's quality of life. In conclusion, high-quality clinical studies are needed to aid clinicians in developing and applying molecular biomarkers as well as standard treatment guidelines.

Indexed as

ArecaArecolineBiomarkersCollagenHumansMouth MucosaMouth NeoplasmsOral Submucous FibrosisRisk FactorsArecolineBiomarkersCollagenbiomarkersepidemiologyoral submucous fibrosis (OSF)pre-malignant disorderstherapeutic interventions

Identifiers

PMID33008091
PMCPMC7582467
OpenAlexW3090222693

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.